Anti-TNF-α therapy modulates resistin in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 26, Issue 2, 2008, Pages 311-316

  Gonzalez Gay, Miguel A ^a   Garcia Unzueta, Maria T ^a   Gonzalez Juanatey, Carlos ^b   Miranda Filloy, Jose A ^a   Vazquez Rodriguez, Tomas R ^a   de Matias, Jose Martin ^c   Martin, Javier ^d   Dessein, Patrick H ^e   Llorca, Javier ^f  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Division of Cardiology   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d CSIC   (Spain)

^e Faculty of Health Sciences   (South Africa)

^f UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Anti TNF antibody infliximab; Inflammation; Resistin; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CHLOROQUINE; CYCLOSPORIN A; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; GOLD; INFLIXIMAB; LEFLUNOMIDE; LOSARTAN; METHOTREXATE; NAPROXEN; PREDNISONE; RESISTIN; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; THROMBOCYTE COUNT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43349098447     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. GONZALEZ-GAY MA,AGONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
2. DEL RINCÓN I, ESCALANTE A: Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 278-86.
3. GAZI IF, BOUMPAS DT, MIKHAILIDIS DP, GANOTAKIS ES: Clustering of cardiovascular risk factors in rheumatoid arthritis: The rationale for using statins. Clin Exp Rheumatol 2007; 25: 102-11.
4. DEL RINCÓN I, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A: High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
5. DESSEIN PH, JOFFE BI, VELLER MG et al.: Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435-42.
6. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
7. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
8. SATTAR N, MCCAREY DW, CAPELL H, MCINNES IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
9. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
10. IMPERATO AK, BINGHAM CO 3RD, ABRAMSON SB: Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22: S108-14.
11. CARMONA L, DESCALZO MA, PEREZ-PAMPIN E et al.: All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists. Ann Rheum Dis 2007; 66: 880-5.
12. HÜRLIMANN D, FORSTER A, NOLL G et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.
13. GONZALEZ-JUANATEY C, TESTA A, GARCIA-CASTELO A, GARCIA-PORRUA C, LLORCA J, GONZALEZ-GAY MA: Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-50.
14. GONZALEZ-JUANATEY C, LLORCA J, SANCHEZ-ANDRADE A, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006; 24: 309-12.
15. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al.: Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24:83-6.
16. STEPPAN CM, BROWN EJ, WRIGHT CM et al.: A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98: 502-6.
17. STEPPAN CM, BAILEY ST, BHAT S et al.: The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
18. LEE JH, CHAN JL, YIANNAKOURIS N, KONTOGIANNI M et al.: Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-56.
19. PATEL L, BUCKELS AC, KINGHORN IJ et al.: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-6.
20. KASER S, KASER A, SANDHOFER A, EBENBICHLER CF, TILG H, PATSCH JR: Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286-90.
21. SCHAFFLER A, EHLING A, NEUMANN E et al.: Adipocytokines in synovial fluid. JAMA 2003; 290: 1709-10.
22. MIGITA K, MAEDA Y, MIYASHITA T et al.: The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24: 698-701.
23. SENOLT L, HOUSA D, VERNEROVA Z et al.: Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 458-63.
24. BOKAREWA M, NAGAEV I, DAHLBERG L, SMITH U, TARKOWSKI A: Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-95.
25. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, DE MATIAS JM et al.: Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
26. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
27. VIS M, NURMOHAMED MT, WOLBINK G et al.: Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32:252-5.
28. VAN GESTEL AM, STUCKI G: Evaluation of established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999; 13: 629-44.
29. ALETAHA D, WARD MM, MACHOLD KP, NEIL VP, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
30. OTERO M, LAGO R, GOMEZ R et al.: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.
31. LEHRKE M, REILLY MP, MILLINGTON SC, IQBAL N, RADER DJ, LAZAR MA: An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1: E45.
32. SATTAR N, MCINNES IB: Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-92.
33. GOODSON NJ, SYMMONS DP, SCOTT DG, BUNN D, LUNT M, SILMAN AJ: Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293-9.
34. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, PINEIRO A, GARCIA-PORRUA C, TESTA A, LLORCA J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1219-23.
35. VERMA S, WANG CH, LI SH, DUMONT AS, FEDAK PW, BADIWALA MV et al.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-9.
36. REILLY MP, LEHRKE M, WOLFE ML, ROHATGI A, LAZAR MA, RADER DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-9.